TREACE MEDICAL CONCEPTS INC
For the period ended Sep 30, 2024. Filed Nov 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 5, 2024
TMCI$4.88+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(55,242) | $(43,246) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and amortization expense | 6,182 | 3,583 |
| Provision for allowance for credit losses | 2,381 | 79 |
| Share-based compensation expense | 22,048 | 11,480 |
| Non-cash lease expense | 607 | 1,868 |
| Amortization of debt issuance costs | 223 | 223 |
| Accretion (amortization) of discount (premium) on marketable securities, net | (918) | (1,031) |
| Other, net | 180 | 164 |
| Net changes in operating assets and liabilities, net of acquisitions | ||
| Accounts receivable | 11,505 | 4,121 |
| Inventory | (14,366) | (9,915) |
| Prepaid expenses and other assets | 838 | (1,028) |
| Other non-current assets | (312) | — |
| Operating lease liabilities | (147) | 497 |
| Accounts payable | 6,814 | 12 |
| Accrued liabilities | (12,753) | (1,954) |
| Other, net | — | 40 |
| Net cash provided by (used in) operating activities | (32,960) | (35,107) |
| Cash flows from investing activities | ||
| Purchases of available-for-sale marketable securities | (52,890) | (140,075) |
| Sales and maturities of available-for-sale marketable securities | 93,363 | 82,979 |
| Purchases of property and equipment | (8,519) | (9,210) |
| Acquisition, net of cash acquired | — | (20,000) |
| Net cash provided by (used in) investing activities | 31,954 | (86,306) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock from public offering, net of issuance costs and underwriting discount of $7.5 million | — | 107,527 |
| Proceeds from exercise of employee stock options | 371 | 1,691 |
| Taxes from withheld shares | (237) | — |
| Net cash provided by (used in) financing activities | 134 | 109,218 |
| Net increase (decrease) in cash and cash equivalents | (872) | (12,195) |
| Cash and cash equivalents at beginning of period | 12,982 | 19,473 |
| Cash and cash equivalents at end of period | $12,110 | $7,278 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $3,732 | $3,863 |
| Operating lease right-of-use asset and lease liability adjustment due to lease incentive | $88 | $(22) |
| Noncash investing activities | ||
| Unrealized (gains) losses, net on marketable securities | $(28) | $121 |
| Unsettled marketable security purchase and payable to broker | $— | $(1,100) |
| Unsettled matured marketable security and receivable from broker | $— | $6,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.